Autoantigens plus interleukin-10 suppress diabetes autoimmunity

Area of Science:

• Immunology
• Virology
• Endocrinology

Background:

• Type 1 diabetes mellitus (T1DM) is an autoimmune disease.
• Previous attempts using recombinant vaccinia virus (rVV) expressing CTB::GAD or IL-10 alone showed limited immune suppression for T1DM.
• A combination strategy was hypothesized to enhance therapeutic efficacy.

Purpose of the Study:

• To evaluate the efficacy of a combined rVV strategy for T1DM immunotherapy.
• To assess the long-term protection against hyperglycemia and insulitis in non-obese diabetic (NOD) mice.

Main Methods:

• NOD mice were co-infected with rVV expressing CTB::GAD and rVV expressing IL-10 (rVV-CTB::GAD + rVV-IL10).
• Mice were monitored for hyperglycemia development from 12 to 64 weeks of age.
• Pancreatic insulitis and splenocyte cytokine profiles (interferon-gamma, IL-10) were analyzed.

Main Results:

• Co-inoculation with rVV-CTB::GAD + rVV-IL10 significantly reduced hyperglycemia incidence (20% by 28 weeks) compared to controls (54-80% by 36 weeks).
• Independent rVV therapies (CTB::GAD or IL-10) showed no significant protection.
• Histological analysis revealed reduced insulitis in euglycemic mice receiving the combined therapy.

Conclusions:

• Combinatorial vaccinia virus vaccination with CTB::GAD and IL-10 provides effective and durable euglycemia in prediabetic NOD mice.
• This strategy promotes immunological homeostasis and reduces pancreatic inflammation.
• The findings suggest a promising immunotherapeutic approach for T1DM.